| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
1 Department of Radiology, University of Michigan Hospitals, 1500 E. Medical
Center Dr., Ann Arbor, MI 48109-0030.
2 Department of Internal Medicine, University of Michigan Hospitals, Ann Arbor,
MI 48109.
OBJECTIVE. Our aim was to determine which of three contrast-enhanced phases (early arterial, late arterial, or portal venous) was optimal for achieving maximal enhancement of the celiac artery, portal vein, and hepatic parenchyma. We also wanted to learn which phase provided the maximal tumor-to-parenchyma difference when using multidetector CT (MDCT) with fixed timing delays.
MATERIALS AND METHODS. Fifty-two patients with suspected or known hepatic tumors underwent multiphasic contrast-enhanced MDCT using double arterial (early and late arterial) and venous phase acquisitions with fixed timing delays. All patients were administered 150 mL of IV contrast material at an injection rate of 4 mL/sec. Images were acquired at 20 sec for the early arterial phase, 35 sec for the late arterial phase, and 60 sec for the portal venous phase. Attenuation measurements of the celiac artery, portal vein, normal hepatic parenchyma, and the hepatic tumor were compared. Three reviewers independently and subjectively rated tumor conspicuity for each of the three phases. Ratings were compared using kappa statistics.
RESULTS. Late arterial phase images showed maximal celiac axis attenuation, whereas portal venous phase images revealed the highest portal vein and normal hepatic parenchymal attenuation. Maximal tumor-to-parenchyma differences for hypovascular tumors was superior in the portal venous phase, but we found no significant differences in maximal tumor-to-parenchyma differences for hypervascular tumors among the evaluated phases. On subjective analysis, interobserver agreement was moderate to very good for the three phases. All three reviewers graded both hypovascular and hypervascular tumor conspicuity as superior in either the late arterial phase or the portal venous phase in most patients. In only one patient was the early arterial phase graded as superior to the late arterial and portal venous phases (by two of the three reviewers).
CONCLUSION. When MDCT of the liver is performed using fixed timing delays, maximal vascular and hepatic parenchymal enhancement is achieved on either late arterial phase or portal venous phase imaging. In most patients, early arterial phase imaging does not improve tumor conspicuity by either quantitative or subjective analysis.
CiteULike 
Complore 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
This article has been cited by other articles:
|
|
 |
|
  C. H. McCollough, L. Guimaraes, and J. G. Fletcher In Defense of Body CT Am. J. Roentgenol., July 1, 2009; 193(1): 28 - 39. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y K KIM, C S KIM, and Y M HAN Detection of small hepatocellular carcinoma: comparison of conventional gadolinium-enhanced MRI with gadolinium-enhanced MRI after the administration of ferucarbotran Br. J. Radiol., June 1, 2009; 82(978): 468 - 484. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. Yanaga, K. Awai, T. Nakaura, T. Namimoto, S. Oda, Y. Funama, and Y. Yamashita Optimal Contrast Dose for Depiction of Hypervascular Hepatocellular Carcinoma at Dynamic CT Using 64-MDCT Am. J. Roentgenol., April 1, 2008; 190(4): 1003 - 1009. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Nakaura, K. Awai, Y. Yanaga, Y. Nakayama, S. Oda, Y. Funama, and Y. Yamashita Detection of Early Enhancement of Hypervascular Hepatocellular Carcinoma Using Single Breath-Hold 3D Pixel Shift Dynamic Subtraction MDCT Am. J. Roentgenol., January 1, 2008; 190(1): W13 - W18. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
A. Ronzoni, D. Artioli, R. Scardina, L. Battistig, E. Minola, S. Sironi, and A. Vanzulli Role of MDCT in the Diagnosis of Hepatocellular Carcinoma in Patients with Cirrhosis Undergoing Orthotopic Liver Transplantation Am. J. Roentgenol., October 1, 2007; 189(4): 792 - 798. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M.-J. Kim, J. Y. Choi, J. S. Lim, J. Y. Kim, J. H. Kim, Y. T. Oh, E. H. Yoo, J. J. Chung, and K. W. Kim Optimal scan window for detection of hypervascular hepatocellular carcinomas during MDCT examination. Am. J. Roentgenol., July 1, 2006; 187(1): 198 - 206. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. T. Johnson and E. K. Fishman IV Contrast Selection for MDCT: Current Thoughts and Practice Am. J. Roentgenol., February 1, 2006; 186(2): 406 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
Y. K. Kim, C. S. Kim, G. H. Chung, Y.-M. Han, S. Y. Lee, S. B. Chon, and J. M. Lee Comparison of Gadobenate Dimeglumine-Enhanced Dynamic MRI and 16-MDCT for the Detection of Hepatocellular Carcinoma Am. J. Roentgenol., January 1, 2006; 186(1): 149 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Awai, M. Inoue, Y. Yagyu, M. Watanabe, T. Sano, S. Nin, R. Koike, Y. Nishimura, and Y. Yamashita Moderate versus High Concentration of Contrast Material for Aortic and Hepatic Enhancement and Tumor-to-Liver Contrast at Multi-Detector Row CT Radiology, December 1, 2004; 233(3): 682 - 688. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. V. Sahani and S. P. Kalva Imaging the Liver Oncologist, July 1, 2004; 9(4): 385 - 397. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
